Critical Quality Attribute Investigation and Analytical Method Establishment for Glyco-Site-Specific Anti-HER2 Bispecific ADC.

izalontamab brengitecan (BL-B01D1) - Sichuan Biokin Pharmaceutical, BMS, Systimmune

http://www.ncbi.nlm.nih.gov/pubmed/42797539

Chuanfei Yu; Lan Wang; Lele Wang; Tao Tang; Weirong Cao; Xiaojuan Yu; Yalan Yang; Yan Li; Yangwei Fu; Yao Tang

Sep 27, 2026